OverviewChartProfileKey statisticsFinancialsNewsTraderScreen

SWEDISH ORPHAN BIOVIT.SK1/  SE0000872095  /

gettex
8/9/2024  9:43:47 PM Chg. +0.220 Volume Bid9:58:00 PM Ask9:58:00 PM Market Capitalization Dividend Y. P/E Ratio
24.220EUR +0.92% 65
Turnover: 1,572.200		 24.240Bid Size: 309 24.260Ask Size: 309 8.6 bill.EUR - -
GlobeNewswire 5/24 Sobi to present new myelofibrosis data at the ASCO 2024 Annual Meeting
GlobeNewswire 5/24 Sobi Receives US FDA Fast Track Designation for Emapalumab-lzsg being investigated in Macrophage Act...
GlobeNewswire 9/7/2021 Nature Medicine publishes positive phase 3 anakinra study results in patients with COVID-19 pneumoni...
GlobeNewswire 12/22/2020 FDA Approves KINERET® (anakinra) for the Treatment of Deficiency of IL-1 Receptor Antagonist (DIRA)
GlobeNewswire 5/4/2016 Swedish Orphan Biovitrum AB (publ): Bo Jesper Hansen sells 8 million shares
GlobeNewswire 4/29/2016 Sobi signs manufacturing agreements with Pfizer
GlobeNewswire 4/27/2016 Sobi publishes its report for the first quarter 2016
GlobeNewswire 4/27/2016 Sobi publishes 2015 Annual Report
GlobeNewswire 4/26/2016 Orfadin® Oral Suspension approved in the US
GlobeNewswire 4/22/2016 Sobi signs licensing agreement with Affibody for IL-1
GlobeNewswire 4/21/2016 European patent granted on new formulation of Kineret® (anakinra)
GlobeNewswire 4/20/2016 Notice of annual general meeting in Swedish Orphan Biovitrum AB (publ)
GlobeNewswire 4/11/2016 COMP recommends that Alprolix® maintains orphan designation for treatment of haemophilia B
GlobeNewswire 3/24/2016 European Commission approves transfer of marketing authorisation for Elocta® to Sobi
GlobeNewswire 3/8/2016 Sobi announces new date for Annual General Meeting of shareholders
GlobeNewswire 2/29/2016 Sobi updates outlook for 2016
GlobeNewswire 2/26/2016 Sobi and Biogen receive positive opinion from CHMP for Alprolix® (rFIXFc) for the treatment of haemo...
GlobeNewswire 2/26/2016 Bo Jesper Hansen to step down as Chairman of Sobi - Håkan Björklund to be nominated as new Chairman ...
GlobeNewswire 2/26/2016 Sobi publishes its report for the fourth quarter and full year 2015
GlobeNewswire 2/23/2016 Sobi to initiate clinical development programs in acute gout and Still's disease, and receives US pa...
GlobeNewswire 2/17/2016 Invitation - Presentation of Sobi's fourth quarter and full year results 2015
GlobeNewswire 1/28/2016 Sobi to present new interim ASPIRE data at EAHAD congress suggesting that patients can reduce bleedi...
GlobeNewswire 1/19/2016 Sobi's Orfadin® oral suspension granted European patent
GlobeNewswire 1/14/2016 Chief Medical Officer Birgitte Volck to leave Sobi
GlobeNewswire 1/11/2016 Sobi(TM) announces commercial launch of Elocta® in first countries in Europe